Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.32 |
| ▸ | MTTP | P55157 | 1/20 | 0.31 |
| ▸ | GCGR | P47871 | 1/20 | 0.31 |
| ▸ | GIPR | P48546 | 1/20 | 0.31 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9972773 | 1.00 | SMO (0.33) | SMORAF1BRAFMCHR1MTTP | |
| SCHEMBL15214844 | 0.98 | MTTP (0.33) | SMORAF1BRAFMCHR1MTTP | |
| SCHEMBL1960109 | 0.98 | MTTP (0.33) | SMORAF1BRAFMCHR1MTTP | |
| SCHEMBL1962042 | 0.98 | RAF1 (0.31) | SMORAF1BRAF | |
| SCHEMBL12553415 | 0.98 | RAF1 (0.31) | SMORAF1BRAF | |
| SCHEMBL1964161 | 0.97 | PLG (0.32) | SMORAF1BRAFMCHR1GCGR | |
| SCHEMBL9973011 | 0.97 | PLG (0.32) | SMORAF1BRAFMCHR1GCGR | |
| SCHEMBL12553402 | 0.96 | MGAT2 (0.32) | SMOMCHR1MGAT2 | |
| SCHEMBL9973069 | 0.96 | MTTP (0.32) | SMORAF1BRAFMTTPGCGR | |
| SCHEMBL1963225 | 0.96 | MTTP (0.32) | SMORAF1BRAFMTTPGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2718754-B1 | POLARIZING PHOTOCHROMIC ARTICLES | TRANSITIONS OPTICAL INC (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-2969499-B1 | METHOD OF PREPARING PHOTOCHROMIC-DICHROIC FILMS HAVING REDUCED OPTICAL DISTORTION | TRANSITIONS OPTICAL INC (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-2969468-B1 | METHOD OF PREPARING PHOTOCHROMIC-DICHROIC FILMS HAVING REDUCED OPTICAL DISTORTION | TRANSITIONS OPTICAL INC (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3045971-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | Transitions Optical, Inc. (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2652553-B1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL INC (US) | 2016-04-06 | — | — | EP | disclosed |
| US-9030740-B2 | Photochromic article having at least partially crossed polarized photochromic-dichroic and fixed-polarized layers | TRANSITIONS OPTICAL, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140264979-A1 | METHOD OF PREPARING PHOTOCHROMIC-DICHROIC FILMS HAVING REDUCED OPTICAL DISTORTION | TRANSITIONS OPTICAL LIMITED (IE) | 2014-09-18 | — | — | US | disclosed |
| US-20140078583-A1 | Photochromic Article Having At Least Partially Crossed Polarized Photochromic-Dichroic And Fixed-Polarized Layers | TRANSITIONS OPTICAL, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8649081-B1 | Photochromic article having two at least partially crossed photochromic-dichroic layers | TRANSITIONS OPTICAL, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-8545015-B2 | Polarizing photochromic articles | TRANSITIONS OPTICAL, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8518546-B2 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110143141-A1 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110143141-A1 | Photochromic compounds and compositions | CCNA1, CRY1, CCNT1 | SMO 778/4885RAF1 3521/4885BRAF 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.